Suppr超能文献

臭椿酮通过体外和体内细胞周期阻滞及凋亡抑制Huh7癌细胞生长。

Ailanthone Inhibits Huh7 Cancer Cell Growth via Cell Cycle Arrest and Apoptosis In Vitro and In Vivo.

作者信息

Zhuo Zhenjian, Hu Jianyang, Yang Xiaolin, Chen Minfen, Lei Xueping, Deng Lijuan, Yao Nan, Peng Qunlong, Chen Zhesheng, Ye Wencai, Zhang Dongmei

机构信息

Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drug Research, College of Pharmacy, Jinan University, Guangzhou 510632, China.

Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, United States.

出版信息

Sci Rep. 2015 Nov 3;5:16185. doi: 10.1038/srep16185.

Abstract

While searching for natural anti-hepatocellular carcinoma (HCC) components in Ailanthus altissima, we discovered that ailanthone had potent antineoplastic activity against HCC. However, the molecular mechanisms underlying the antitumor effect of ailanthone on HCC have not been examined. In this study, the antitumor activity and the underlying mechanisms of ailanthone were evaluated in vitro and in vivo. Mechanistic studies showed that ailanthone induced G0/G1-phase cell cycle arrest, as indicated by decreased expression of cyclins and CDKs and increased expression of p21 and p27. Our results demonstrated that ailanthone triggered DNA damage characterized by activation of the ATM/ATR pathway. Moreover, ailanthone-induced cell death was associated with apoptosis, as evidenced by an increased ratio of cells in the subG1 phase and by PARP cleavage and caspase activation. Ailanthone-induced apoptosis was mitochondrion-mediated and involved the PI3K/AKT signaling pathway in Huh7 cells. In vivo studies demonstrated that ailanthone inhibited the growth and angiogenesis of tumor xenografts without significant secondary adverse effects, indicating its safety for treating HCC. In conclusion, our study is the first to report the efficacy of ailanthone against Huh7 cells and to elucidate its underlying molecular mechanisms. These findings suggest that ailanthone is a potential agent for the treatment of liver cancer.

摘要

在寻找臭椿中天然抗肝细胞癌(HCC)成分的过程中,我们发现臭椿酮对HCC具有强大的抗肿瘤活性。然而,臭椿酮对HCC抗肿瘤作用的分子机制尚未得到研究。在本研究中,我们在体外和体内评估了臭椿酮的抗肿瘤活性及其潜在机制。机制研究表明,臭椿酮诱导G0/G1期细胞周期阻滞,表现为细胞周期蛋白和细胞周期蛋白依赖性激酶(CDK)表达降低,p21和p27表达增加。我们的结果表明,臭椿酮引发了以ATM/ATR通路激活为特征的DNA损伤。此外,臭椿酮诱导的细胞死亡与凋亡相关,表现为亚G1期细胞比例增加以及聚(ADP-核糖)聚合酶(PARP)裂解和半胱天冬酶激活。在Huh7细胞中,臭椿酮诱导的凋亡是由线粒体介导的,并且涉及PI3K/AKT信号通路。体内研究表明,臭椿酮抑制肿瘤异种移植的生长和血管生成,且无明显的继发性不良反应,表明其对治疗HCC具有安全性。总之,我们的研究首次报道了臭椿酮对Huh7细胞的疗效,并阐明了其潜在的分子机制。这些发现表明臭椿酮是一种治疗肝癌的潜在药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aca4/4630794/faf3d128aec2/srep16185-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验